A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) - Regional Cancer Care Associates LLC

Clinical Trials

A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Type of Cancer
Lymphoma
Locations
Bethesda
Sponsor
Seattle Genetics
Protocol Number
SGN33A-005
Cancer Diagnosis
To Learn More Call
201-510-0910